CONFERENCES
ISRAEL NEWS
HEALTH & WELLNESS
WORLD NEWS
MIDDLE EAST
BUSINESS & INNOVATION
OPINION
JP STORE
Login
Login
Subscribe
JPOST DIGITAL LIBRARY
HOME PAGE
BUSINESS & INNOVATION
OPINION
REAL ESTATE LISTINGS
ALIYAH
JERUSALEM POST CONFERENCE
PREMIUM
JP STORE
Categories
ISRAEL NEWS
WORLD NEWS
MIDDLE EAST
ARAB ISRAELI CONFLICT
US POLITICS
DIASPORA
OPINION
PODCAST
JUDAISM
KABBALAH
CHRISTIAN WORLD
HEALTH & WELLNESS
SCIENCE
LAW
ARCHAEOLOGY
OMG
ENVIRONMENT & CLIMATE CHANGE
FOOD & RECIPES
JERUSALEM POST EN ESPANOL
HISTORY
SPONSORED CONTENT
ADVERTISE WITH US
TERMS OF USE
PRIVACY POLICY
CONTACT US
CANCEL SUBSCRIPTION
CUSTOMER SERVICE
ABOUT US
Jerusalem Post
/
Health & Wellness
/
Mental Health
This Alzheimer's drug was called a 'breakthrough,' so why did 3 people die?
Lecanemab was hailed by headlines as a breakthrough treatment for Alzheimer's. Now, with the death of a third patient, there are concerns about this medication.
Alzheimer's disease (illustrative).
(photo credit:
VIA WIKIMEDIA COMMONS
)
By
JERUSALEM POST STAFF
,
WALLA! HEALTH
APRIL 18, 2023 13:48
See more on
drugs
|
medicine
|
death
|
Alzheimer
|
FDA - Food and Drug Administration
|
Brain damage
|
Brain
RECOMMENDED STORIES
Admitting defeat? Why Hamas officials say the terror group 'lost control' of Gaza
JULY 7, 2025
'Security situation has collapsed': Hamas has lost 80% of its control over Gaza Strip
JULY 7, 2025
Reporter's Notebook: 'Post' meets with top Hebron sheikh who wants to pull out of PA
JULY 6, 2025
IDF cyber chief, retired Iran strategy head piloted fighter jets striking Iran
JULY 6, 2025
Hot Opinion
The tragic case of IDF soldier's suicide shows we must do more for our fighters
By
JPOST EDITORIAL
Iran at a crossroads: Intelligence breaches, internal paranoia shake the regime
By
SALEM ALKETBI
Is an Iran nuclear deal still possible after the US-Israel strikes?
By
CHUCK FREILICH
Paying for the 'day after': Who will fund Gaza’s reconstruction?
By
NEVILLE TELLER